首页> 外文期刊>Journal of Medical Microbiology: An Official Journal of the Pathological Society of Great Britain and Ireland >Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital
【24h】

Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital

机译:中国医院泌尿生殖道标本中人支原体对氟喹诺酮耐药的机制研究

获取原文
           

摘要

Purpose.Mycoplasma hominis is considered among the causes of urogenital infections and shows increasing resistance to fluoroquinolones. However, data regarding the fluoroquinolone resistance mechanism of M. hominis in Southwest China are limited. This study aimed to investigate gene mutations of quinolone resistance-determining regions (QRDRs) of M. hominis isolated from clinical urogenital samples in a Chinese hospital.Methodology. Strains of M. hominis were identified by 16S rRNA gene sequencing. The minimal inhibitory concentrations (MICs) of fluoroquinolones were determined by the broth microdilution method, following CLSI guidelines. PCR was used to amplify the QRDRs of the genes gyrA, gyrB, parC and parE. Positive products were sequenced, and gene mutations and amino acid substitutions were analysed by DNAMAN software and BLAST.Results. The resistance rates of M. hominis to ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF) and gatifloxacin (GAT) were 90.5, 85.7, 73.8 and 71.4?%, respectively. A total of 57 isolates of M. hominis were screened, among which 52 strains demonstrated different resistant phenotypes to fluoroquinolones, 41 harboured amino acid substitutions of GyrA S153L, 51 harboured ParC S91I and 22 harboured ParC K144R. ParE A463S and ParC A154T were recorded for the first time and no amino acid change was detected in GyrB.Conclusion. The resistance of M. hominis to fluoroquinolones in Southwest China is mainly related to mutations in QRDRs of either gyrA or parC. High-level resistance is associated with mutations in both DNA gyrase and topoisomerase IV.
机译:目的。人型支原体被认为是泌尿生殖道感染的原因之一,并且显示出对氟喹诺酮类药物的耐药性增加。然而,有关西南地区人型分枝杆菌对氟喹诺酮耐药机制的数据有限。这项研究旨在调查从中国一家泌尿生殖器临床样本中分离出的人型支原体喹诺酮耐药性决定区(QRDRs)的基因突变。通过16S rRNA基因测序鉴定人型分枝杆菌。遵循CLSI指南,通过肉汤微量稀释法确定氟喹诺酮类药物的最低抑菌浓度(MIC)。 PCR用于扩增gyrA,gyrB,parC和parE基因的QRDR。对阳性产物进行测序,并通过DNAMAN软件和BLAST分析基因突变和氨基酸取代。人型分枝杆菌对环丙沙星(CIP),左氧氟沙星(LVX),莫西沙星(MXF)和加替沙星(GAT)的耐药率分别为90.5%,85.7%,73.8%和71.4%。共筛选了57株人型分枝杆菌,其中52株对氟喹诺酮类药物表现出不同的抗性表型,GyrA S153L的氨基酸替换为41,ParC S91I的替换为51,ParC K144R的替换为22。首次记录了ParE A463S和ParC A154T,在GyrB中未检测到氨基酸变化。中国西南地区的人型分枝杆菌对氟喹诺酮类药物的耐药性主要与gyrA或parC的QRDR突变有关。高水平的耐药性与DNA促旋酶和拓扑异构酶IV的突变有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号